|
Market Closed -
Hong Kong S.E.
01:38:09 02/10/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 9.930 HKD | -1.39% |
|
+6.43% | +17.79% |
| 02/10 | Major drugmakers turn to China for licensing deals | RE |
| 01/10 | CSPC Reports Blood Sugar Reduction in Phase III Diabetes Study | MT |
Company Valuation: CSPC Pharmaceutical Group Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,00,932 | 97,707 | 86,022 | 55,169 | 96,380 | 1,13,361 | - | - |
| Change | - | -3.19% | -11.96% | -35.87% | 74.7% | 17.62% | - | - |
| Enterprise Value (EV) 1 | 89,633 | 86,241 | 72,284 | 46,931 | 86,710 | 1,02,144 | 99,076 | 95,935 |
| Change | - | -3.79% | -16.18% | -35.07% | 84.76% | 17.8% | -3% | -3.17% |
| P/E | 14.7x | 14.1x | 13.5x | 12.1x | 21.8x | 11.2x | 16.5x | 15.5x |
| PBR | 3.17x | 2.86x | 2.39x | 1.62x | 2.56x | 2.53x | 2.36x | 2.19x |
| PEG | - | 14.13x | -1.73x | -0.5x | -9.88x | 0x | -0.5x | 2.34x |
| Capitalization / Revenue | 2.94x | 2.77x | 2.52x | 1.78x | 3.26x | 2.95x | 3.18x | 3x |
| EV / Revenue | 2.61x | 2.44x | 2.12x | 1.51x | 2.94x | 2.66x | 2.78x | 2.54x |
| EV / EBITDA | 9.5x | 9.43x | 8.39x | 6.22x | 12.1x | 7.44x | 10.3x | 8.99x |
| EV / EBIT | 10.7x | 10.8x | 9.77x | 7.68x | 15.6x | 8.39x | 12.3x | 11.3x |
| EV / FCF | 23.7x | 14.1x | 26.2x | 17.5x | 19.5x | 13.4x | 14.9x | 13.9x |
| FCF Yield | 4.22% | 7.11% | 3.82% | 5.71% | 5.12% | 7.48% | 6.7% | 7.2% |
| Dividend per Share 2 | 0.18 | 0.21 | 0.28 | 0.26 | 0.29 | 0.4597 | 0.3682 | 0.3914 |
| Rate of return | 2.13% | 2.56% | 3.86% | 5.44% | 3.44% | 4.63% | 3.71% | 3.94% |
| EPS 2 | 0.5773 | 0.5831 | 0.5376 | 0.3946 | 0.3859 | 0.8882 | 0.6023 | 0.6422 |
| Distribution rate | 31.2% | 36% | 52.1% | 65.9% | 75.2% | 51.7% | 61.1% | 60.9% |
| Net sales 1 | 34,309 | 35,292 | 34,175 | 31,046 | 29,533 | 38,470 | 35,682 | 37,813 |
| EBITDA 1 | 9,431 | 9,148 | 8,615 | 7,547 | 7,168 | 13,722 | 9,579 | 10,675 |
| EBIT 1 | 8,366 | 7,952 | 7,400 | 6,113 | 5,564 | 12,178 | 8,040 | 8,468 |
| Net income 1 | 6,901 | 6,949 | 6,382 | 4,632 | 4,409 | 10,141 | 7,017 | 7,508 |
| Net Debt 1 | -11,298 | -11,467 | -13,738 | -8,238 | -9,670 | -11,217 | -14,285 | -17,426 |
| Reference price 2 | 8.470 | 8.200 | 7.260 | 4.780 | 8.430 | 9.930 | 9.930 | 9.930 |
| Nbr of stocks (in thousands) | 1,19,16,370 | 1,19,15,520 | 1,18,48,756 | 1,15,41,665 | 1,14,33,025 | 1,14,16,025 | - | - |
| Announcement Date | 22/03/22 | 22/03/23 | 20/03/24 | 28/03/25 | 25/03/26 | - | - | - |
1HKD in Million2HKD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 11.18x | 2.66x | 7.44x | 4.63% | 1.44TCr | |
| 32.45x | 11.78x | 23.93x | 0.61% | 1,01900Cr | |
| 28.48x | 6.32x | 17.7x | 2.09% | 62TCr | |
| 33.26x | 7.78x | 16.08x | 2.64% | 46TCr | |
| 104.98x | 5.87x | 24.89x | 2.36% | 36TCr | |
| 18.81x | 4.58x | 11.36x | 2.9% | 33TCr | |
| 19.83x | 5.17x | 12.78x | 3.09% | 27TCr | |
| 20.02x | 4.17x | 11.86x | 2.13% | 24TCr | |
| 25.46x | 6.66x | 11.86x | 2.5% | 22TCr | |
| -43.78x | 6.39x | 24.97x | 2.27% | 18TCr | |
| Average | 25.07x | 6.14x | 16.29x | 2.52% | 37.12TCr | |
| Weighted average by Cap. | 31.72x | 7.59x | 18.56x | 1.97% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 1093 Stock
- Valuation CSPC Pharmaceutical Group Limited
Select your edition
All financial news and data tailored to specific country editions
